Known targets — ChEMBL curated mechanism
ABL1BCRBLKEPHA2FGRFRKFYNHCKKITLCKLYNPDGFRBSRCSRMSYES1
The experimentally established mechanism targets of Dasatinib Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 10/20 | 1.00 |
| ▸ | SRC known ✓ | P12931 | 5/20 | 1.00 |
| ▸ | LCK known ✓ | P06239 | 4/20 | 1.00 |
| ▸ | FYN known ✓ | P06241 | 2/20 | 1.00 |
| ▸ | YES1 known ✓ | P07947 | 2/20 | 1.00 |
| ▸ | LYN known ✓ | P07948 | 2/20 | 1.00 |
| ▸ | HCK known ✓ | P08631 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 2/20 | 1.00 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 1.00 |
| ▸ | FRK known ✓ | P42685 | 2/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.98 |
| ▸ | FGR known ✓ | P09769 | 1/20 | 0.98 |
| ▸ | BLK known ✓ | P51451 | 1/20 | 0.98 |
| ▸ | SRMS known ✓ | Q9H3Y6 | 1/20 | 0.98 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | CSF1R | P07333 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dasatinib Anhydrous SCHEMBL28350326 | 1.00 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL29381185 | 1.00 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL28828268 | 0.99 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL29377489 | 0.99 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL290515 | 0.99 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL16618598 | 0.99 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL28432270 | 0.99 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL1705152 | 0.99 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL20857008 | 0.99 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL29482416 | 0.99 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 62688 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144750-A1 | Dosing Regimens for Treatment of Glioblastoma | SIGNPATH PHARMA INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3836899-B1 | CHEMOTHERAPEUTIC PHARMACEUTICAL SUSPENSION FOR ORAL DOSAGE | ONCOSOL LTD (GB) | 2026-05-27 | — | — | EP | claimed |
| EP-4746852-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2026-05-27 | — | — | EP | claimed |
| EP-4507690-B1 | COMBINATION OF DASATINIB AND LOVASTATIN FOR USE IN METHODS FOR THE TREATMENT OF CARDIAC FIBROSIS | INST NAT SANTE RECH MED (FR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260137638-A1 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | TYARDI OPERATING CO INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20050009891-A1 | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-13 | — | — | US | claimed |
| US-20040209930-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | claimed |
| EP-1169038-A4 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | claimed |
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | DAS JAGABANDHU (US) | 2004-04-22 | — | — | US | claimed |
| US-20040073026-A1 | Autoimmune diseases; anticancer agents | DAS JAGABANDHU (US) | 2004-04-15 | — | — | US | claimed |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | claimed |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | DAS JAGABANDHU (US) | 2004-02-05 | — | — | US | claimed |
| US-6596746-B1 | protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders; dasatinib | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | claimed |
| EP-1169038-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-09 | — | — | EP | claimed |
| WO-2000062778-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-26 | — | — | WO | claimed |